• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, July 13, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Joseph Moskal elected to medical and biological engineering elite

Bioengineer by Bioengineer
February 14, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Sally Ryan

Northwestern University's Joseph R. Moskal has been elected to the American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows. Moskal was cited for his studies of the NMDA receptor, which have led to the design and development of novel therapeutics for the treatment of depression.

Moskal, a distinguished research professor in Northwestern's Department of Biomedical Engineering, is among 145 engineers who make up the College of Fellows Class of 2017. They will be inducted during AIMBE's 2017 annual meeting on March 20 in Washington, D.C.

The College of Fellows comprises the top two percent of medical and biological engineers in the country. Current AIMBE Fellows have received some of the nation's highest awards, including the Presidential Medal of Science and Presidential Medal of Technology and Innovation. Many are also members of the National Academy of Engineering, National Academy of Medicine, and National Academy of Sciences.

"I am honored to join such an elite group of engineers," said Moskal, founding director of Northwestern's Falk Center for Molecular Therapeutics. "I hope this will help motivate the next generation to continue to develop what we have only begun to understand."

Moskal founded and served as chief scientific officer of Naurex, Inc., a drug discovery company that develops therapies for difficult-to-treat depression and other central nervous system diseases. While at Naurex, his team developed rapastinel, a novel therapy for treatment-resistant major depression, which is now in phase III clinical trials. In 2015, Allergan acquired Naurex for $1.7 billion.

Now, Moskal is the co-founder of Aptinyx, Inc., which targets areas of pain, post-traumatic stress disorder, and traumatic brain injury for therapeutic development. Last year, he was inducted into the National Academy of Inventors and the Chicago Area Entrepreneurship Hall of Fame.

###

Media Contact

Megan Fellman
[email protected]
847-491-3115
@northwesternu

http://www.northwestern.edu

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

New Tick-Borne Threat: Anaplasmosis Spreads in Canada

July 13, 2026

Paid Work Linked to Cognitive Benefits in Older Chinese Adults

July 13, 2026

Bioinspired Microcapsule Reactor Using Engineered Probiotics for IBD Treatment

July 13, 2026

KAIST Uncovers Key to Overcoming Semiconductor Electrical Bottleneck

July 13, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13
  • Experimental Therapy Simultaneously Destroys Prostate Tumor Cells and Reactivates Antitumor Immunity

    46 shares
    Share 18 Tweet 12

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Tick-Borne Threat: Anaplasmosis Spreads in Canada

Paid Work Linked to Cognitive Benefits in Older Chinese Adults

Bioinspired Microcapsule Reactor Using Engineered Probiotics for IBD Treatment

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.